PE Has $2.5T Sitting Idle. It's Coming for Dentistry.

Private equity is sitting on $1.3 trillion of unspent buyout money, and it is simultaneously stuck with 32,000 portfolio companies worth $3.8 trillion that it cannot sell, according to Bain & Company's Global Private Equity Report 2026. Round the pressure however you like, somewhere north of $2 trillion in capital that has to move and can't: the consequence for you is that a sector with 180,000 owner-operated small businesses, fragmented payer contracts and no public comparables starts to look like the only door left open.

Here's the part most owners won't like. Our view: if you are more than seven years from hanging up the loupes, a PE-backed sale at today's multiples is a bad trade, and the $1.3 trillion overhang is precisely the reason it's bad rather than the reason it's good. The money arriving at your door is not arriving because dentistry got more valuable. It's arriving because the exits elsewhere are jammed.

$1.3 Trillion Has to Go Somewhere, and Fast

Dry powder is not patient capital. It's committed capital on a clock, raised from pensions and endowments that were promised a return inside a fund life. Bain's numbers describe a system where average holding periods have stretched to roughly seven years and 32,000 companies are waiting for a buyer that hasn't shown up. When the normal path (buy a platform, grow it, sell it to a bigger fund) stops clearing, firms do two things: they hold longer, and they hunt for sectors where the entry multiple is still low enough that the math works even with a slow exit.

Dentistry is that sector. Single-location practices still trade at low-to-mid single-digit multiples of adjusted earnings. Assemble twenty of them under one management company, centralize billing and supply purchasing, and the assembled entity gets valued like a healthcare services platform instead of twenty small businesses. The gap between what the buyer pays you and what the buyer's buyer pays for the bundle is the whole business model. It has nothing to do with your hygiene recall rate.

That's not a scandal. It's arithmetic, and it has been running for a decade. What's changed is urgency. A fund that needs to deploy before its investment period closes is a different counterparty from a fund shopping for a bargain, and you should price that difference into every conversation.

Seven Years Matters More Than 16.1%

The consolidation numbers are real and they're moving. DSO affiliation among U.S. dentists hit 16.1% in 2024, more than double the 7.2% recorded in 2015, per ADA Health Policy Institute data reported by DentistryIQ. The climb was steady rather than sudden: 8.8% in 2017, 10.4% in 2019, 13% in 2022, as ADA News documented. Nobody should be surprised by the trend line.

But 16.1% is a lagging indicator and a soft one. The number with teeth is the early-career figure: more than one in four dentists within ten years of graduation now work with a DSO, up from 23% in 2022. That is your associate pipeline, your eventual internal buyer, and your competition for hiring, all in one statistic.

Pair it with the other seven-year number. Bain says the average PE holding period is now about seven years. If you roll equity into a platform today, you are underwriting a liquidity event that the sponsor's own track record says may not arrive until 2033, in a market where 32,000 companies are already queued ahead of you. You will have no say in the timing, no mark you can trust, and no way to sell your stake to anyone except the sponsor who issued it.

What Most Owners Get Wrong: Rollover Equity Isn't Money

The specific mistake, and it is almost always made by owners in their late fifties with one strong location and no CFO, is treating the headline enterprise value as the deal. The broker says $1.58 million. The owner tells their spouse $1.58 million. The term sheet says 70% cash at close and 30% rollover, and the owner mentally books the rollover at face value because it's printed in dollars.

It isn't dollars. It's a minority position in a debt-loaded holding company, priced by the party that controls both the valuation and the exit, with no put right, no tag-along protection worth the paper in a down round, and a capital structure where preferred equity sits above you. Owners who have never read a waterfall provision are signing documents whose entire economic content is the waterfall provision.

The second mistake, made by the same owners: accepting a post-close associate agreement without pricing the income they're giving up. You stop being the person who takes home the earnings. You become a scheduled producer on a percentage, with a non-compete, inside a company that now decides your supply vendors and your recall protocol.

A $1.58M Offer That Needs a 2.5x Miracle

Run it. Take a single-location general practice collecting $1.6 million, with adjusted EBITDA of $288,000 after charging a market-rate dentist salary against the books. The Bureau of Labor Statistics puts the median annual wage for dentists at $176,110 as of May 2025, so that's the compensation line a buyer will normalize to.

At 5.5x, enterprise value is $1,584,000. Structured 70/30, you take $1,108,800 in cash at close and $475,200 in rollover equity. Assume a blended 25% effective rate on the cash portion, and you clear $831,600 after tax.

Now the other side. Pre-sale, you were taking $288,000 of earnings plus $176,110 of clinical compensation, so $464,110 a year. Post-sale you produce $900,000 at a 30% associate rate, so $270,000. The annual gap is $194,110. Over the seven-year holding period Bain says is now typical, that's $1,358,770 of forgone income.

Your after-tax cash at close covers $831,600 of it, leaving a $527,170 hole. To fill that hole after tax, the rollover has to throw off $702,893 of gain. Add your basis and the stake needs to be worth $1,178,093 at exit , which is 2.48 times what you put in.

And that's just break-even. It gets you back to where you'd have been by doing nothing, and it assumes the exit happens on schedule, at a multiple at least as good as today's, with no preferred stack eating the first slice and no additional equity issued above you in the meantime. Meanwhile the do-nothing case leaves you still owning a practice at the end of year seven.

We wouldn't take that deal. Not at 5.5x with 30% rolled into an illiquid minority stake in a market where a third of a trillion dollars' worth of sponsors can't find buyers for what they already own. The number to negotiate isn't the multiple. It's the cash percentage.

Colorado Tried to Ban the Landlord

There's a second risk nobody prices, and it's regulatory. Colorado's Dental Board adopted Rule 1.7, effective June 30, 2026, barring DSOs from serving as practice proprietors or owning practice real estate and equipment, per the Colorado Dental Association. The rule is stayed pending a Court of Appeals challenge the Association of Dental Support Organizations drove, filed July 16, 2026.

Whichever way Colorado lands, the signal is the thing. State boards are now willing to legislate against the specific mechanics of the management-company structure, including the real estate holding that makes many of these deals pencil. If you rolled equity into a platform with heavy exposure in a state that follows Colorado's lead, the asset you're holding gets repriced by people who never asked your opinion. Corporate practice of dentistry rules vary enormously by state, and the acquirer's lawyers know your state's rules better than you do.

Who Should Actually Say Yes

We're not against selling. There are owners for whom today's bid is a gift, and they share three traits.

• They're inside five years of stopping clinical work, so the forgone-income math shrinks toward zero and the cash at close is most of the deal.
• They have no internal successor and no realistic associate buyer, which given that more than a quarter of dentists in their first decade are already affiliated is an increasingly common position.
• They can negotiate 85% or more in cash, or they genuinely don't need the rollover proceeds to fund anything.

If you fit all three, take the meeting and take the money. Demand employment-term protections in writing, get a hard floor on your production percentage, and have a healthcare transactions attorney (not your general counsel, not your CPA) read the waterfall and the non-compete before you read the purchase price out loud to anyone.

Employment demand, for what it's worth, is on your side: BLS projects dentist employment to grow 6% from 2025 to 2035, faster than the all-occupation average, with roughly 9,000 openings over the decade. You are not selling into a dying trade. You're selling into a crowded buying trade, which is a very different thing.

Three Things to Do Before Your Next Broker Call

Pull your trailing twelve months and calculate adjusted EBITDA yourself, charging a real market salary against your production, so the first number in the room is yours. Ask any interested party for the vintage of the fund that would hold your practice and when its investment period closes, because a fund with eighteen months left to deploy will pay more than one with five years. Then model your deal at 100% cash, at 70/30 with the rollover valued at zero, and only then at the sponsor's projection. If the deal only works in the third scenario, you don't have a deal, you have a pitch.

What we're tracking: whether the Colorado appeal produces a published opinion other state boards can copy, and whether cash-at-close percentages in dental deals start sliding below 70% as sponsors conserve capital for the companies they already can't sell. If exit activity reopens and holding periods compress back toward four years, the rollover math changes materially and we'll say so. Until then, understand what's happening when the fourth unsolicited letter arrives this quarter. You are not being courted. You are being inventoried.

Before you respond to any letter, get a defensible number on your own practice. Our free valuation calculator runs adjusted EBITDA and multiple ranges on your actual collections and overhead so you walk into the conversation knowing what the asset is worth without a broker telling you: run your own numbers.